Clinical trial
A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)
NCT04993755 is registered in ClinicalTrials.gov with Transposon Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)
- Lead sponsor
- Transposon Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 1, 2021
- Completion date
- September 1, 2023
- Enrollment
- 42 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.